Clinical Trials Logo

Multiorgan Failure clinical trials

View clinical trials related to Multiorgan Failure.

Filter by:
  • None
  • Page 1

NCT ID: NCT05874895 Recruiting - Sepsis Clinical Trials

MAnual Lymphatic DrAinage to iMprove the outcomE of Patients After Septic Shock

MADAME
Start date: June 1, 2023
Phase: N/A
Study type: Interventional

Antimicrobial and supportive therapeutic interventions in patients with septic shock are usually effective - procalcitonin and interleukin-6 levels fall rapidly in most cases, and noradrenaline support can be discontinued within a few days. Unfortunately, only in a small portion of patients, do the organ functions improve at the same time, and in most of them, multi-organ failure persists. Therefore, it is likely that, in addition to infection and the response to infection, other mechanisms are also involved in the persistence of organ failure in patients after septic shock.

NCT ID: NCT05181696 Recruiting - Sepsis Clinical Trials

Retrospective Analysis of Chest X-ray Severity Scoring System of COVID-19 Pneumonia

RANCH-COVID
Start date: January 1, 2020
Phase:
Study type: Observational

The research will be retrospective, and will include all patients who were admitted during 2020 and 2021 in the COVID-19 ICU of University Hospital Center Osijek due to pneumonia caused by the Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The association of chest x-ray infiltrate evolution with changes in laboratory inflammatory parameters and respiratory function parameters will be examined.

NCT ID: NCT05044403 Not yet recruiting - Sepsis Clinical Trials

Evaluation of the Efficacy and Safety of Extracorporeal Support With Hemoperfusion in Critical Patients With Multiorgan Dysfunction Syndrome by Septic Origin

Start date: October 1, 2021
Phase: Phase 4
Study type: Interventional

Low-level interventional clinical trial to evaluate the effectiveness and safety of extracorporeal support with hemoperfusion in critical patients with multiorgan dysfunction syndrome by septic origin.

NCT ID: NCT04004481 Completed - Respiratory Failure Clinical Trials

Metabolites of Tramadol in the Postoperative Surgical Patients

METRAS
Start date: January 25, 2019
Phase:
Study type: Observational

Tramadol is opioid analgesic widely used to treat moderate to severe pain. It is metabolized by cytochrome CYP2D6 into two major metabolites: pharmacologically active metabolite O-desmethyltramadol (M1) and inactive N-desmethyltramadol (M2), respectively. Tramadol kinetics in a population of patients undergoing major abdominal surgical procedures, and in patients with a greater or lesser degree of organic failure, is still not well researched. The investigators will measure plasma concentrations of tramadol and its metabolites after usual tramadol doses in ICU patients after major abdominal surgery. Also analgesic affect and side effect of tramadol will be recorded.

NCT ID: NCT03875352 Completed - Surgery Clinical Trials

The Influence of Nursing Technique Applied at the Central Venous Catheter Insertion Site Upon the Incidence of Infection

Start date: February 1, 2016
Phase: N/A
Study type: Interventional

Assessing the impact of the nursing technique applied at the insertion site of the central venous catheter using hydrophilic methacrylate gel (HMG) and 2% Chlorhexidine (CHG) upon the incidence of inflammatory complications when treating the surrounding of the central venous catheter.

NCT ID: NCT03604731 Completed - Sepsis Clinical Trials

Persistent Multiorgan Failure in Intensive Care Units

PROPOSe
Start date: January 1, 2017
Phase:
Study type: Observational [Patient Registry]

Multiorgan failure (MOF) as a result of any critical condition is a complex set of immunological and biochemical interactions leading to death in patients who are effectively subjected to primary resuscitation (correction of circulatory hypoxia in trauma and blood loss, restoration of blood circulation after operations with artificial circulation. The frequency of MOF varies depending on the primary diagnosis of a critical patient and, according to a number of authors, is 60% for sepsis, and for severe co-occurring trauma up to 40% of all critical patients. However, if one remembers that the MOF is verified only by clinical scales of assessing the severity of the patient's condition, which presupposes the presence of the already existing pathophysiological mechanisms of MOF as multi-organ dysfunction, it is possible to declare a 100% presence of MOF in all critical patients. The data of Graetz et al (2016) show that none of the available three variants of pathophysiological mechanisms (anomaly of microcirculation, persistent inflammation, immune suppression and catabolism, cellular hibernation and staning) have been unambiguously demonstrated, which also reflected the lack of effectiveness of methods therapy, proposed, based on the pathogenesis options for MOF. A so-called danger-model has a special place in the genesis of the persistence of the MOF, which justifies an active search for distress-associated and pathogen-associated molecular patterns for their objectification and probable elimination. The systemic inflammatory response in patients. included in the study, is not a primary infection. It is also important to determine the role of danger-associated molecular patterns (DAMP) in the genesis of immune suppression as the leading immunological phenotype of MOF in later periods and to evaluate the relationship between DAMP expression and immunosuppressive cells of monocyte origin. The study has a mixed (retro- and prospective) character.

NCT ID: NCT03281707 Not yet recruiting - Clinical trials for Perfusion; Complications

NIRS and DO2i Correlation

Start date: September 30, 2017
Phase: N/A
Study type: Observational [Patient Registry]

This study evaluates the association between near infrared spectroscopy (NIRS) and indexed oxygen delivery (DO2i) and their possible correlation with postoperative organ failure.